Financial Highlights
- Financial Review FY2020
In medical and care service industries, medical workers struggled for COVID-19. We sincerely would like to express deep appreciation for your devoted works on the frontiers against COVID-19.
Sales in FY2020 increased 1.7%. Due to COVID-19, negotiations of renewal contracts were impeded, some deliveries of our products, Healthcare wear and Doctors’ wear to medical institutions delayed, and some contracts were postponed to FY2021. Our new COVID-19 prevention products, which we developed in this term, contributed to total growth.
Gross profit to sales in FY2020 decreased 0.9 point(45.8%). Production cost rose, because to meet sharp increase in demand of new COVID-19 prevention products, we realized quick response by using productive capacity in Japan.
| % Change | ||
|---|---|---|
| Net sales | ¥17,066 million | ＋1.7 % |
| Gross profit to sales | 45.8 % | -0.9 point |
| Operating income | ¥4,937 million | +0.4 % |
| Net income | ¥3,474 million | +0.8 % |
| Total assets | ¥44,931 million | +1.5 % |
| Capital-to-asset ratio | 89.3% |
